Table 2.
Detection of disease involvement in multiple myeloma using 99mTc-sestamibi planar plus single-photon emission computed tomography/computed tomography and 18F-fluorodeoxyglucose PET/computed tomography
| FDG-PET/CT | MIBI planar + SPECT/CT | |
|---|---|---|
| Detection of any disease involvement (n) | 59 (95%) | 58 (93%) |
| CT lytic lesions without radiotracer uptake (n) | 4 (6%) | 3 (5%) |
| Focal lesions with radiotracer uptake (n) | 19 (31%) | 7 (12%) |
| Diffuse bone marrow involvement (n) | 5 (8%) | 22 (36%) |
| Focal lesions + diffuse bone marrow involvement (n) | 31 (50%) | 26 (42%) |
| Number of focal lesions (n) | ||
| Group A (1–3 lesions) | 11 (17.5%) | 17 (28.5%) |
| Group B (4–10 lesions) | 16 (25.5%) | 6 (9.5%) |
| Group C (>10 lesions) | 23 (38%) | 10 (16%) |
| Contiguous soft tissue involvement (n) | 28 (45%) | 23 (37%) |
| Extra osseous lesions (n) | 4 (6%) | 1 (1.5%) |
| Median SUVmax (range) | 5.3 (1.9–34.7) |
FDG, 18F-fluorodeoxiglucose; MIBI, 99mTc-sestamibi; n = number of patients.